viningocouqyl1601.blogspot.com
Hematide is in a Phase III trial. Rentomn led Onyx for nearly 15 stepping down in February 2008as CEO, chairman and a member of Onyx’ s board. At the company, he helpedr negotiate a research, developmentg and commercialization partnership with that resulted inthe anti-cancerf drug Nexavar. Nexavar tablets, which cost about $5,000 a month in the United States and areapproaching $1 billion in annual sales, are approved in more than 80 countriees to treat kidney cancer and 70-plux countries for liver cancer. Prior to joining Onyx, Renton was president and COO of which acquired Cetusin 1991. Renton had been president of Cetuzsince 1990, COO since 1987 and CFO from 1983 to 1987.
Rento n also serves on the boardsof , Cepheid and the Speciapl Olympics of Northern California.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment